Acetylation and deacetylation of histone in adipocyte differentiation and the potential significance in cancer

• Published in: Translational oncology Vol. 39; p. 101815
• Main Authors: Wang, Xiaorui, Li, Na, Zheng, Minying, Yu, Yongjun, Zhang, Shiwu
• Format: Journal Article
• Language: English
• Published: Elsevier 01.01.2024
• Subjects: Acetylation modifications; Adipocyte differentiation; Cancer stem cells; Histones; Polyploid giant tumor cells
• ISSN: 1936-5233; 1936-5233
• DOI: 10.1016/j.tranon.2023.101815

Adipocytes are derived from pluripotent mesenchymal stem cells and can develop into several cell types including adipocytes, myocytes, chondrocytes, and osteocytes. Adipocyte differentiation is regulated by a variety of transcription factors and signaling pathways. Various epigenetic factors, particularly histone modifications, play key roles in adipocyte differentiation and have indispensable functions in altering chromatin conformation. Histone acetylases and deacetylases participate in the regulation of protein acetylation, mediate transcriptional and post-translational modifications, and directly acetylate or deacetylate various transcription factors and regulatory proteins. The adipocyte differentiation of stem cells plays a key role in various metabolic diseases. Cancer stem cells(CSCs) play an important function in cancer metastasis, recurrence, and drug resistance, and have the characteristics of stem cells. They are expressed in various cell lineages, including adipocytes. Recent studies have shown that cancer stem cells that undergo epithelial-mesenchymal transformation can undergo adipocytic differentiation, thereby reducing the degree of malignancy. This opens up new possibilities for cancer treatment. This review summarizes the regulation of acetylation during adipocyte differentiation, involving the functions of histone acetylating and deacetylating enzymes as well as non-histone acetylation modifications. Mechanistic studies on adipogenesis and acetylation during the differentiation of cancer cells into a benign cell phenotype may help identify new targets for cancer treatment.